1. Introduction {#sec1-viruses-10-00140}
===============

The *Poxviridae* family comprises large DNA viruses that have linear double-stranded genomes and which carry out their entire life cycle within the cytoplasmic compartment of the infected cell \[[@B1-viruses-10-00140],[@B2-viruses-10-00140]\]. Members of this family of viruses have been extensively studied in the last few years aiming at creation of effective poxvirus vector-based vaccines as well as oncolityc vectors \[[@B3-viruses-10-00140],[@B4-viruses-10-00140]\]. Although the World Health Organization declared smallpox eradicated in May 1980, the emergence of zoonotic *Vaccina virus* (VACV) in Brazil and its association with the disease known as bovine vaccinia \[[@B5-viruses-10-00140]\], more studies, nonetheless, are required to better understand VACV-host interactions. *Vaccinia virus* (VACV) is the prototypic poxvirus with a \~200 Kb genome and can infect a broad range of hosts, including rodents and humans \[[@B2-viruses-10-00140],[@B6-viruses-10-00140]\]. About half of VACV genome codes for virus-host interaction products that are implicated in both evading host immune defenses and in creating favorable replicative conditions within cells and tissues \[[@B7-viruses-10-00140],[@B8-viruses-10-00140]\]. Among these are virokines, viroceptors and viral growth factors that act extracellularly, as well as viral proteins that interfere with intracellular signaling pathways \[[@B8-viruses-10-00140],[@B9-viruses-10-00140],[@B10-viruses-10-00140]\]. An example of the former is the Vaccinia growth factor (VGF), a polypeptide that shares sequence and functional similarity to cellular growth factors and is secreted from VACV infected cells to stimulate a proliferative response in surrounding cells \[[@B11-viruses-10-00140],[@B12-viruses-10-00140]\].

The MAPK (Mitogen-Activated Protein Kinase) signaling cascade is a major pathway associated with the transmission of mitogenic and survival signals in response to a variety of extracellular stimuli \[[@B13-viruses-10-00140]\]. Indeed, VACV infection of murine fibroblasts induces the activation of MAPK/ERK1/2 (extracellular-signal-regulated kinase 1/2), which occurs partially through the action of VGF \[[@B10-viruses-10-00140],[@B14-viruses-10-00140],[@B15-viruses-10-00140]\]. This activation appears to facilitate viral replication as inhibition of this pathway has been shown to lead to a large reduction in viral growth \[[@B15-viruses-10-00140]\]. Interestingly, while infection of murine fibroblasts with the rabbit specific leporipoxvirus MYXV (*Myxoma virus*) can also stimulate ERK1/2 phosphorylation, the activation of this pathway renders these cells non-permissive for virus infection through the activation of the transcription factor IRF-3 (Interferon regulatory factor 3) and upregulation of IFN-β (β-Interferon) expression \[[@B9-viruses-10-00140],[@B16-viruses-10-00140]\].

The cellular transcription factor EGR-1 (early growth response-1) was identified as a downstream target of MEK (mitogen-activated protein kinase (MAPK)/ERK)/ERK (extracellular signal-regulated kinases) that is activated during both VACV and CPXV infection \[[@B17-viruses-10-00140]\]. However, this factor appears to play a distinct role during the infections of these two *Orthopoxviruses* as depletion of EGR-1 by siRNA solely affects VACV replication \[[@B16-viruses-10-00140]\]. EGR-1 is an 82 kDa phosphoprotein with a modular structure, containing both a DNA-binding domain equipped with three C2H2 zinc fingers that bind to the consensus DNA sequence 5-GCG(G/T)GGGCG-3 \[[@B18-viruses-10-00140]\] and an activation/repression domain, a structure that is consistent with the diverse activities associated with the molecule \[[@B19-viruses-10-00140],[@B20-viruses-10-00140]\]. EGR-1 couples extracellular stimulation elicited by growth factors, cytokines and environmental stress to cellular responses associated with proliferation, apoptosis and tissue injury \[[@B19-viruses-10-00140],[@B21-viruses-10-00140]\]. Moreover, EGR-1 has recently been implicated in neuronal plasticity and memory formation \[[@B22-viruses-10-00140],[@B23-viruses-10-00140]\], as well as cancer invasion, by upregulating the expression of cysteine protease cathepsin D \[[@B24-viruses-10-00140]\].

Different viruses, such as the KSHV (Kaposi's sarcoma-associated herpesvirus), HSV-1 (herpes simplex virus type-1), JCV (human polyomavirus JC virus), HIV (human immunodeficiency virus) and EBV (Epstein-Barr virus) are also capable of modulating the *egr-1* gene function during infection \[[@B25-viruses-10-00140],[@B26-viruses-10-00140],[@B27-viruses-10-00140],[@B28-viruses-10-00140],[@B29-viruses-10-00140]\].

We show here that deletion of the *egr-1* gene does not affect VACV gene expression or morphogenesis but diminishes the specific infectivity of the virus particles produced in starved cells.

2. Materials and Methods {#sec2-viruses-10-00140}
========================

2.1. Cell Culture, Antibodies and Chemicals {#sec2dot1-viruses-10-00140}
-------------------------------------------

Wild type (WT) and *egr-1* knockout (*egr-1^−/−^*) mouse embryonic fibroblasts (MEFs) from the same genetic background were kindly provided by Dr. Eileen D. Adamson (USA) \[[@B30-viruses-10-00140]\]. The cells were cultured in Dulbecco's modified Eagle's medium (DMEM), supplemented with 7% (*v*/*v*) heat-inactivated fetal bovine serum (FBS) and antibiotics in 5% CO~2~ at 37 °C. Cells were starved after reaching 90% confluence by changing the medium to 0.5% FBS for 12 h. The Rhesus monkey kidney fibroblast cell line BSC-40 (ATCC CRL-2761) was cultured in modified Eagle's medium (MEM), supplemented with 7% (*v*/*v*) (FBS) and antibiotics in 5% CO~2~ at 37 °C. The commercially available antibodies and chemicals used were: rabbit polyclonal antibody against EGR-1 (Santa Cruz Biotech, Dallas, TX, USA), mouse monoclonal anti-β-actin antibody, peroxidase-conjugated anti-rabbit secondary antibody peroxidase-conjugated anti-mouse secondary antibody and the MEK inhibitor U0126 (Cell Signaling, Danvers, MA, USA). The antibodies against the viral proteins A13, D8, H3, F18, A17, p4b/4b and B14 (SPI-2/crmA) were provided by Dr. Bernard Moss (NIAID, Bethesda, MD, USA). The MEK inhibitor U0126 was used at a concentration of 15 µM.

2.2. Virus Infection and Purification {#sec2dot2-viruses-10-00140}
-------------------------------------

Wild type VACV, strain WR, was propagated into BSC-40 cells and purified by sucrose gradient sedimentation as previously described \[[@B31-viruses-10-00140]\]. Infectivity of the purified viruses was determined by the plaque assay in BSC-40 cells. The total number of particles was determined from the OD at 260 nm by using the following formula: 1 OD = 1.2 × 10^10^ particles \[[@B32-viruses-10-00140]\] and confirmed by Bradford analysis of protein content at 595 nm and by real time polymerase chain reaction (PCR) analysis. The experiments presented in this study were carried out with the mature virion (MV) form of VACV. Before infection, cells were cultured until they reached 80--90% confluence and were subsequently serum starved (0.5% FBS, for 12 h). The cells were infected at the indicated multiplicity of infection (MOI) for the times shown.

2.3. Virus Infectivity Assays {#sec2dot3-viruses-10-00140}
-----------------------------

WT or *egr-1^−/−^* MEFs were cultured, serum deprived or not, at a density of 5 × 10^5^ cells per well, on a 6-well culture dish and then VACV-infected. Infections were carried out at an MOI of 10 for 3, 6, 12, 24, 36 and 48 h. Where indicated, cells were incubated with the MEK pharmacological inhibitor U0126 for 30 min prior to infection, which was kept in the media throughout the infection.

Virus present in the disrupted cell lysates was assayed for infectivity. The 48 h.p.i. time-point was run in triplicate and the results represent the average values. Statistical analysis by two-tailed Student's *T*-test was performed with the ABI prism 3.0 software (La Jolla, CA, USA).

2.4. Western Blotting {#sec2dot4-viruses-10-00140}
---------------------

### 2.4.1. Whole-Cell Lysate Preparation {#sec2dot4dot1-viruses-10-00140}

WT or *egr-1^−/−^* MEFs were grown and starved as above and infected with VACV at an MOI of 5 or 10 for the indicated times. Cells were left untreated or were pre-incubated for 30 min with U0126 when indicated, which remained throughout the infection. Cell lysates were generated as described previously \[[@B16-viruses-10-00140]\].

### 2.4.2. Electrophoresis and Immunoblotting {#sec2dot4dot2-viruses-10-00140}

Thirty micrograms of the cell lysate per sample was separated on a 10% SDS-Acrylamide gel and transferred to nitrocellulose membranes. Membranes were blocked, washed and incubated with a specific rabbit polyclonal anti-EGR-1 (1:1500) or anti-viral proteins (1:3000) or mouse monoclonal anti-β-actin (1:3000) antibodies. Immunoreactive bands were visualized using the enhanced chemiluminescence (ECL) detection system (GE Healthcare, São Paulo, Brazil).

2.5. Real Time PCR {#sec2dot5-viruses-10-00140}
------------------

WT or *egr-1^−/−^* MEFs were serum starved or grown in media containing 7% serum and infected with VACV at an MOI of 10. Infections were carried out for 3, 6, 9 or 24h with DNA extraction at each time point through the phenol-chloroform procedure as described previously \[[@B33-viruses-10-00140]\]. Viral load was determined using the primers (F 5′CTGTAGTTATAAACGTTCCGTGTG3′ and R 5′TTATCATACGCATTACCATTTCGA3′) to target the viral RNA polymerase subunit *rpo18* gene (D7R) \[[@B34-viruses-10-00140]\] and the results were normalized using the primers designed for the cellular primate DNA for the IL12p40 subunit gene (F 5′GTAGAGGTGGACTGGACTCC3′ and R 5′CAGATGTGAGTGGGTCAGAG3′). A 5-fold serial dilution of VACV DNA extracted from 48 h infected cells was used as to construct a standard curve in order to validate the experiments. The parameters obtained were: VACV-rpo18 primers (Slope: −3.345; Efficiency: 98.99%; *R*^2^: 0.981) IL12p40 (Slope: −3.385; Efficiency: 97.44%; *R*^2^: 0.983). Viral load was quantified as arbitrary units relative to the reference: 1 = viral load at 3 h.p.i. in WT MEFs (∆∆*C*T method). PCR conditions were as follows: initial denaturation: 5 min at 95 °C followed by 30 cycles of: 30 s at 95 °C, 30 s at 58 °C, 30 s at 72 °C. Graphics and statistical analyses were performed by using ABI Prism 3.0 software (La Jolla, CA, USA).

2.6. Electron Microscopy {#sec2dot6-viruses-10-00140}
------------------------

WT or *egr-1^−/−^* MEFs were maintained in low serum for 24 h and then infected with VACV at an MOI of 2 for 18 h. Cells were washed with phosphate buffered saline (PBS) and fixed in situ with 1% glutaraldehyde in PBS (pH 7.4) for 1 h at room temperature. Cells were then processed for conventional transmission electron microscopy and thin sections were examined on a Hitachi H-600 microscope (São Paulo, Brazil).

3. Results {#sec3-viruses-10-00140}
==========

3.1. EGR-1 Protein Expression Is Stimulated through the MEK/ERK Pathway upon VACV Infection and Is Required for Replication in Starved Fibroblasts {#sec3dot1-viruses-10-00140}
--------------------------------------------------------------------------------------------------------------------------------------------------

This study aimed to address the VACV replication cycle step(s) affected by EGR-1 disruption. To that end, wild-type (WT) MEFs and those with an inactivated *egr-1* locus (*egr-1^−/−^*), generated by Virolle and collaborators \[[@B30-viruses-10-00140]\] were used. Cells were deprived of FBS, that is, 0.1% FBS---12 h and then infected with VACV at an MOI of 10. [Figure 1](#viruses-10-00140-f001){ref-type="fig"}A shows that VACV infection stimulated the expression of EGR-1 protein in the WT MEFs through the MEK/ERK pathway. EGR-1 protein accumulation could be detected by western blotting (WB) from 3 to 12 h.p.i. ([Figure 1](#viruses-10-00140-f001){ref-type="fig"}A, lanes 1--7) and was abolished when the infection was carried out in the presence of the MEK inhibitor, U0126 ([Figure 1](#viruses-10-00140-f001){ref-type="fig"}A, lane 8). As a control, a WB showing the levels of EGR-1 in proliferating as compared to starved cells is shown ([Supplementary Figure S1](#app1-viruses-10-00140){ref-type="app"}). Data concerning the proliferation rates of WT or *egr-1^−/−^* cells growing in the presence of 0.1% or 10% fetal bovine serum (FBS) is also provided ([Supplementary Figure S2](#app1-viruses-10-00140){ref-type="app"}). In addition, VACV growth curve experiments showed that the yield of infectious VACV was decreased by \~1 log when the infection was carried out in serum-starved (FBS−) *egr-1^−/−^* MEFs rather than WT MEFs, as shown in [Figure 1](#viruses-10-00140-f001){ref-type="fig"}B. The same reduction was not observed in VACV yield when the infection was carried out in cycling (not serum-deprived---FBS+) *egr-1^−/−^* MEFs ([Figure 1](#viruses-10-00140-f001){ref-type="fig"}B), suggesting that EGR-1 is required for VACV replication particularly in the intracellular environment of starved cells.

3.2. EGR-1 Gene Deletion Does Not Affect VACV Gene Expression or Morphogenesis in MEFs {#sec3dot2-viruses-10-00140}
--------------------------------------------------------------------------------------

Next, we designed a set of experiments to identify which step of the VACV replication cycle was affected by *egr-1* gene deletion in starved MEFs. Several studies have implicated host cell proteins, such as TBP---TATA-binding protein and G3BP/Caprin 1, in VACV intermediate/late transcription in vitro \[[@B35-viruses-10-00140],[@B36-viruses-10-00140],[@B37-viruses-10-00140],[@B38-viruses-10-00140],[@B39-viruses-10-00140],[@B40-viruses-10-00140]\], therefore we asked whether VACV gene expression would be altered in *egr-1^−/−^* MEFs.

Analysis of WT and *egr-1^−/−^* MEFs infected with VACV under low serum conditions did not reveal any difference in viral gene expression as demonstrated by western blot analyses of either the early protein B14/SPI-2 ([Figure 2](#viruses-10-00140-f002){ref-type="fig"}A) or the late proteins H3, A13, F18 and D8 ([Figure 2](#viruses-10-00140-f002){ref-type="fig"}B). The same results were also verified with the early protein H5, the early/intermediate protein I3 and the late proteins A14. The processing of the viral proteins A17 and p4b/4b ([Figure 2](#viruses-10-00140-f002){ref-type="fig"}C) was unaffected by the absence of EGR-1.

Since *egr-1* gene deletion affects the yield of infectious virus without impairing viral gene expression, we next asked whether virion morphogenesis could be impaired by the absence of EGR-1. WT and *egr-1^−/−^* MEFs were serum starved and subsequently infected with VACV at an MOI of 2 for 18 h, after which the cells were processed for transmission electron microscopy. The full spectrum of virion morphogenesis intermediates was observed in both WT ([Figure 2](#viruses-10-00140-f002){ref-type="fig"}D---panels E--F)) and *egr-1^−/−^* cells ([Figure 2](#viruses-10-00140-f002){ref-type="fig"}D---panels A--D). Virosomes (V, panel A--C and E), membrane crescents (lollipops, panels B,C,E), immature virions (arrowheads, panels A,B,E), immature virions with nucleoids (asterisk, panel C) and mature virions (arrow, panels B--D and F) were seen in abundance. Wrapped virions, which are the precursor of the small pool of enveloped virions that are released from infected cells by exocytosis, were also seen.

3.3. VACV Produced in egr-1^−/−^ MEFs Have Reduced Specific Infectivity {#sec3dot3-viruses-10-00140}
-----------------------------------------------------------------------

Although the yield of infectious VACV in serum-starved *egr-1^−/−^* MEFs was reduced by \~1 log as compared to what we observed in WT MEFs, (neither the biochemical progression of the life cycle nor virion morphogenesis appeared to be impaired). It seemed possible, that virions formed in the absence of EGR-1 might be decreased in their infectivity. In order to address this question VACV was propagated in serum-starved *WT* or *egr-1^−/−^* MEFs at an MOI of 10. To confirm that the same phenotypes observed during VACV infection of *egr-1^−/−^* MEFs with an MOI of 10 occurred under the conditions optimized for electron microscopy analysis (MOI of 2, 18 h.p.i.), these experiments were also performed at an MOI of 10. At 24 h.p.i., cells were collected and the virus particles were purified by sucrose gradient sedimentation. The particle:pfu ratio of purified VACV propagated in *egr-1^−/−^* MEFs (VACV *egr-1^−/−^*) was 4- to 5-fold higher than that of VACV propagated in WT MEFs (VACV WT) ([Figure 3](#viruses-10-00140-f003){ref-type="fig"}A). These results confirm the hypothesis that VACV *egr-1^−/−^* particles possess a decreased level of specific infectivity. A minor 2-fold reduction in the total number of particles produced in *egr-1* knockout cells was also observed ([Figure 3](#viruses-10-00140-f003){ref-type="fig"}A). [Figure 3](#viruses-10-00140-f003){ref-type="fig"}B shows western blot analysis of the mature virions (MV) structural proteins H3 and F18 present in equivalent amounts of purified VACV WT and VACV *egr-1^−/−^* particles propagated at MOI 2 and 10. This assay corroborates the quantification of total virus particles obtained by spectrophotometric analysis and real time PCR shown in [Figure 3](#viruses-10-00140-f003){ref-type="fig"}A.

3.4. VACV Produced in MEFs egr-1^−/−^ Presents Delayed Viral DNA Replication during the Next Round of Infection {#sec3dot4-viruses-10-00140}
---------------------------------------------------------------------------------------------------------------

To determine at which stage(s) of virus replication the reduced infectivity would become evident, BSC-40 cells were infected in parallel with equal numbers of VACV produced in WT and *egr-1^−/−^* MEFs.

BSC-40 were grown in 7% FBS and infected with VACV WT at an MOI of 5.0 or with the corresponding number of VACV *egr-1^−/−^* particles. Viral protein expression and processing ([Figure 4](#viruses-10-00140-f004){ref-type="fig"}A) and viral DNA replication ([Figure 4](#viruses-10-00140-f004){ref-type="fig"}B) were then analyzed at various times post-infection. [Figure 4](#viruses-10-00140-f004){ref-type="fig"}A shows that the expression levels of the early protein B14/SPI-2 were similar regardless if the infections were carried out with VACV that had been propagated in *egr-1^−/−^* or in WT MEFs. The kinetics of protein expression showed similar patterns of protein expression ([Figure 4](#viruses-10-00140-f004){ref-type="fig"}A). By contrast, a statistically significant decrease in the levels of replicated viral DNA was seen in cells infected with VACV propagated in *egr-1^−/−^* MEFs as compared to those infected with VACV propagated in WT MEFs ([Figure 4](#viruses-10-00140-f004){ref-type="fig"}B---left panel). As a control, we also compared the VACV DNA yield with virus produced in WT or *egr-1^−/−^* cells in the presence of 7% FBS. Our result clearly showed that, under this circumstance, there is no difference in the levels of replicating viral DNA ([Figure 4](#viruses-10-00140-f004){ref-type="fig"}B---right panel). Taken together, our results indicate that the decreased infectivity observed with VACV particles produced in starved *egr-1^−/−^* MEFs may be due to defects in DNA replication that do not appear to be a consequence of decreased availability of early viral proteins.

4. Discussion {#sec4-viruses-10-00140}
=============

Host-pathogen relationships provide powerful evolutionary forces that shape biological diversity \[[@B41-viruses-10-00140]\]. Throughout coevolution with their hosts, *orthopoxvirus* genomes have acquired the coding capacity for several gene products that modulate host cell function and therefore act as key determinants of viral tropism and pathogenesis \[[@B6-viruses-10-00140],[@B42-viruses-10-00140]\]. For instance, during VACV infection, the viral protein VGF binds to its cellular receptor EGF and triggers mitogenic signaling cascades, a process that results in the transcriptional activation of cellular genes and promotes cell cycle progression \[[@B9-viruses-10-00140],[@B42-viruses-10-00140],[@B43-viruses-10-00140],[@B44-viruses-10-00140]\]. The action of VGF increases viral replication in quiescent cells in vitro \[[@B10-viruses-10-00140],[@B11-viruses-10-00140]\], synergizes with F1L in the inhibition of apoptosis during VACV infection \[[@B45-viruses-10-00140]\] and enhances viral biodistribution and virulence in vivo \[[@B46-viruses-10-00140]\].

It has been demonstrated that mitogenic stimulation creates a favorable environment for the replication of several viruses such as papillomaviruses and adenoviruses. Poxviruses also display greater infectivity in cycling cells ([Figure 1](#viruses-10-00140-f001){ref-type="fig"}B; reviewed in \[[@B8-viruses-10-00140]\]). We have previously shown that VACV infection---partially through the action of VGF---leads to MAPK pathway activation and the consequent expression of the cellular genes *c-fos* and *egr-1* \[[@B13-viruses-10-00140],[@B14-viruses-10-00140]\]. Furthermore, activation of the MEK/ERK/EGR-1 pathway facilitates specifically VACV replication in the A31 cell line as demonstrated by siRNA gene targeting against EGR-1 \[[@B16-viruses-10-00140]\]. In this study, we demonstrate that infection of WT MEFs by VACV stimulates a similar pattern of EGR-1 expression through the MEK/ERK pathway ([Figure 1](#viruses-10-00140-f001){ref-type="fig"}A). However, while EGR-1 expression in MEFs ([Figure 1](#viruses-10-00140-f001){ref-type="fig"}A) ceases earlier than in A31 cells, loss of function of EGR-1 had the same impact on VACV replication as previously reported \[[@B16-viruses-10-00140]\], since *egr-1* gene deletion decreased VACV growth by \~1 log ([Figure 1](#viruses-10-00140-f001){ref-type="fig"}B), a phenomenon restricted to serum-starved mouse cells ([Figure 1](#viruses-10-00140-f001){ref-type="fig"}B). Whether the decrease in EGR-1 expression reflects targeting of the protein for degradation, transcription turning off or both remains an issue to be pursued further. Thus, in line with the fact that EGR-1 is a downstream target of VGF \[[@B14-viruses-10-00140]\] our data suggest that this cellular transcription factor is required specifically in the intracellular environment of starved cells.

Several studies have implicated the cellular transcription factors SP1, YY1 and TBP, as well as the RNA binding proteins G3BP/Caprin-1 in VACV intermediate/late transcription in vitro \[[@B35-viruses-10-00140],[@B36-viruses-10-00140],[@B38-viruses-10-00140],[@B47-viruses-10-00140]\]. These host cell proteins were also shown to colocalize with VACV DNA factories during infection \[[@B35-viruses-10-00140],[@B39-viruses-10-00140],[@B40-viruses-10-00140]\]. Indeed, VACV post-replication transcription complexes require cellular factors for efficient transcription \[[@B48-viruses-10-00140],[@B49-viruses-10-00140],[@B50-viruses-10-00140]\]. This does not seem to be the case for EGR-1 though, since we were unable to detect any interaction of EGR-1 with intermediate/late viral promoter sequences and viral transcriptional complexes by EMSA. Analysis of the subcellular localization of EGR-1 during VACV infection also revealed a nuclear restricted localization of the protein \[[@B16-viruses-10-00140]\]. In addition, the results presented in [Figure 2](#viruses-10-00140-f002){ref-type="fig"}A and [Figure 2](#viruses-10-00140-f002){ref-type="fig"}B do not provide evidence for EGR-1 participation in VACV gene expression, since neither early ([Figure 2](#viruses-10-00140-f002){ref-type="fig"}A) nor intermediate/late ([Figure 2](#viruses-10-00140-f002){ref-type="fig"}B) protein expression was affected in starved *egr-1^−/−^* MEFs.

Further analysis revealed that neither VACV proteolytic processing of late proteins ([Figure 2](#viruses-10-00140-f002){ref-type="fig"}C) nor morphogenesis ([Figure 2](#viruses-10-00140-f002){ref-type="fig"}D) was impacted in *egr-1^−/−^* MEFs. All the stages of viral morphogenesis were observed, at comparable abundance, in both WT and *egr-1^−/−^* MEFs ([Figure 2](#viruses-10-00140-f002){ref-type="fig"}D) (Reviewed in \[[@B1-viruses-10-00140],[@B2-viruses-10-00140]\]). In line with these findings, as shown in [Figure 3](#viruses-10-00140-f003){ref-type="fig"}A, VACV particles produced in starved *egr-1^−/−^* MEFs had a 4--5-fold reduction in their specific infectivity, with only a slight (\~2-fold) reduction in the total number of particles ([Figure 3](#viruses-10-00140-f003){ref-type="fig"}A). Taken together, these results indicate that EGR-1 deletion has little effect on VACV particle formation but it appears to impact the infectivity of the viral particles formed.

We further investigated the progression of a subsequent round of infection performed in BSC40 cells with equal numbers of VACV particles produced in starved WT or *egr-1^−/−^* MEFs ([Figure 4](#viruses-10-00140-f004){ref-type="fig"}A,B). While viral early protein expression appeared to proceed normally in cells infected with VACV *egr-1^−/−^* particles ([Figure 4](#viruses-10-00140-f004){ref-type="fig"}A), the accumulation of viral DNA ([Figure 4](#viruses-10-00140-f004){ref-type="fig"}B). It is important to note that the EGR-1 protein cannot be directly responsible for this phenotype as EGR-1 was not found in purified WT VACV particles by either western blot analysis or mass spectrometry \[[@B51-viruses-10-00140],[@B52-viruses-10-00140]\]. In addition, EGR-1 protein was no longer detectable in cell extracts from infected cells at later times during infection ([Figure 1](#viruses-10-00140-f001){ref-type="fig"}A). It has been shown that VACV encoded uracil DNA glycosylase and dUTPase activities are required for normal viral DNA replication in the intracellular environment of quiescent cells \[[@B53-viruses-10-00140]\]. Studies conducted by Mo and collaborators \[[@B44-viruses-10-00140]\] reveal that *Orf virus* regulates cell cycle progression to S phase while repressing progression through G2/M, creating a supportive intracellular environment for viral genome replication. Although the mechanism through which EGR-1 facilitates VACV replication remains elusive, we hypothesize that this cellular protein might exert a role in reprogramming gene expression in quiescent cells during viral infection. The observation that VACV *egr-1^−/−^* particles express early proteins in similar patterns as WT particles ([Figure 4](#viruses-10-00140-f004){ref-type="fig"}A) suggests that the DNA encapsidated in VACV propagated into *egr-1^−/−^* cells might be itself in some way altered. In line with this observation our previous data demonstrated that EGR-1 expression is regulated by the transcription factor JUN through the binding of JUN to the AP-1 sequence found at the promoter region of *egr-1.* Moreover, viral DNA synthesis was affected in cell line expressing c-Jun dominant-negative mutation \[[@B54-viruses-10-00140]\]. We conclude, based on the fact that JUN expression at times where viral DNA is synthesized \[[@B55-viruses-10-00140]\] is governed by the MEK/ERK pathway \[[@B13-viruses-10-00140],[@B14-viruses-10-00140],[@B54-viruses-10-00140]\] and that the MEK/ERK/JUN/EGR pathway is required for maximal viral DNA synthesis. This may reflect an altered conformation that impairs proper DNA replication, or it may result from the absence of an as yet unknown encapsidated factor that aids replication. However, future studies aiming to address these issues are required.

Our findings reveal VACV specific adaptations for optimal replication in a starved intracellular environment. It would also be of interest to evaluate the tropism and oncolytic potential of recombinant *Orthopoxviruses* expressing dominant-negative forms for EGR-1 protein in vivo.
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![Expression of early growth response-1 EGR-1 protein during *Vaccina virus* (VACV) infection and effects of its deletion in viral replication. (**A**) VACV infection stimulates EGR-1 expression through the MEK (mitogen-activated protein kinase (MAPK)/ERK)/ERK (extracellular signal-regulated kinases) pathway with similar patterns---Western blotting analysis of VACV-infected wild type (WT) mouse embryonic fibroblasts (MEFs) at a multiplicity of infection (MOI) of 10 for the times indicated. Cells were starved with 0.1% fetal bovine serum (FBS) for 12 h and then were either Mock-infected or infected with VACV (lanes 3--8). Where indicated, cells were incubated for 30 min with the MEK inhibitor U0126 (15 µM) prior to and throughout the course of infection (lane 8). The molecular masses are indicated (KDa) on the left. (**B**) VACV growth curve performed with MEFs WT and *egr-1^−/−^*---Cells were infected with VACV at an MOI of 10 for 3, 6, 12, 24, 36 or 48 h. Infection occurred in the presence of 7% FBS (FBS+) (Cycling MEFs) or 0.5% FBS (FBS−) (starved MEFs). Cell-associated virus was then collected and titrated. Data is representative of three independent experiments also titrated in triplicates with similar results (*N* = 3, \* = *p* \< 0.001). Statistical analyses were performed by using ABI Prism 3.0 software.](viruses-10-00140-g001){#viruses-10-00140-f001}

![*Egr-1* gene deletion does not affect VACV gene expression, protein processing or viral morphogenesis. (**A**--**C**) *Egr-1* gene deletion does not affect VACV gene expression or protein processing---Western blotting analysis of VACV infected WT and *egr-1^−/−^* starved MEFs (FBS 0.1%) at an MOI of 10 for the indicated times and with the following antibodies: ((**2A**)---Early viral gene expression) anti-B14 antibody; ((**2B**)---Late viral gene expression) anti-H3, A13, F18 and D8 antibodies; ((**2C**)---Viral protein processing) anti-A17 and -p4b/4b antibodies. The molecular masses are indicated (KDa) on the left. (**D**) *Egr-1* gene deletion does not affect VACV morphogenesis---Confluent monolayers of WT and *egr^−/−^* MEFs were serum-starved for 12 h and infected with VACV for 18 h at an MOI of 2. Cells were then fixed in situ and processed for transmission electron microscopy. WT (panels e,f) and *egr^−/−^* MEFs (panels a--d) contained all the normal intermediates in virion morphogenesis. Simbols---arrowheads: Immature virions; V: Virosomes; lollipops: Crescents; arrows: Mature virions; asterisk: Immature virions with nucleoids; Mature virions with proper brick-shaped morphology and biconcave core: arrows (panel d). Scale bar: a,c---200 nm. b,e,f---400 nm. d---100 nm. Data are representative of three independent experiments with similar results.](viruses-10-00140-g002){#viruses-10-00140-f002}

![VACV formed in *egr-1^−/−^* MEFs presents decreased infectivity. (**A**) Table showing the particle:pfu ratio (specific infectivity) of VACV propagated in WT and *egr-1^−/−^* MEFs. VACV was propagated in serum starved WT and *egr-1^−/−^* MEFs at an MOI of 10 or 2. After 48 h.p.i. virus was collected and purified. Infectivity of the purified viruses was determined by the plaque assay in BSC-40 cells. The total number of particles was determined from the OD at 260 nm by using the formula 1 OD = 1.2 × 10^10^ particles \[[@B32-viruses-10-00140]\] and was confirmed by both the Bradford analysis of protein content at 595 nm and by real time PCR. Data present the mean values of two independent experiments, with each MOI; (**B**) western blot analysis of VACV particles propagated in WT and *egr-1^−/−^* MEFs. Equivalent amounts of WT VACV and *egr-1^−/−^* VACV particles were submitted to SDS-PAGE and immunoblotting with anti-H3 and anti-F18 antibodies to corroborate spectrophotometric quantification of virus particles. Data are representative of two independent experiments, with each MOI, with similar results.](viruses-10-00140-g003){#viruses-10-00140-f003}

![VACV formed in *egr-1^−/−^* MEFs presents delayed viral DNA replication. (**A**)---VACV produced in *egr-1^−/−^* MEFS exhibit no defect in viral early gene expression. Western blotting analysis of BSC-40 cells infected with VACV WT at an MOI of 5 or the corresponding amount of VACV propagated into *egr-1^−/−^* for the indicated times. (**A**)---The membrane was probed with the anti-viral protein antibodies: B14/SPI 2. Bottom panels---Anti β-actin antibody was used as a loading control. Data are representative of three independent experiments. (**B**)---VACV from *egr-1^−/−^* MEFs presents defects in viral DNA replication. Graphic representation of viral DNA accumulation in BSC-40 cells infected with VACV at an MOI of 5 propagated in WT or the corresponding amount of VACV propagated in *egr-1^−/−^* cells as determined by quantitative real time PCR analysis (left panel). The same experiment was also performed with VACV produced in WT or *egr-1^−/−^* cells that were grown in the presence of 7% FBS (right panel). Viral load was quantified as arbitrary units relative to the reference: 1= viral load at 3 h.p.i. in WT MEFs (∆∆*C*~T~ method). A 5-fold serial dilution of VACV DNA extracted from 48 h infected cells was used as to construct a standard curve in order to validate the experiments. The parameters obtained were: VACV-rpo18 primers (Slope: −3.345; Efficiency: 98.99%; *R*^2^: 0.981) IL12p40 (Slope: −3.385; Efficiency: 97.44%; *R*^2^: 0.983). Data are representative of three independent experiments (*N* = 3, \* = *p* \< 0.001). Statistical analyses were performed by using ABI Prism 6.0 software.](viruses-10-00140-g004){#viruses-10-00140-f004}
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